Yuan Ji
YOU?
Author Swipe
View article: Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across Studies
Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across Studies Open
We introduce a Bayesian nonparametric inference approach for aggregate adverse event (AE) monitoring across studies. The proposed model seamlessly integrates external data from historical trials to define a relevant background rate and acc…
View article: Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data Open
Phase I oncology trials aim to identify a safe yet effective dose - often the maximum tolerated dose (MTD) - for subsequent studies. Conventional designs focus on population-level toxicity modeling, with recent attention on leveraging phar…
View article: SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials
SIMBA -- A Bayesian Decision Framework for the Identification of Optimal Biomarker Subgroups for Cancer Basket Clinical Trials Open
We consider basket trials in which a biomarker-targeting drug may be efficacious for patients across different disease indications. Patients are enrolled if their cells exhibit some levels of biomarker expression. The threshold level is al…
View article: Circulating molecules reflect imaging biomarkers of hemorrhage in cerebral cavernous malformations
Circulating molecules reflect imaging biomarkers of hemorrhage in cerebral cavernous malformations Open
Increases in mean lesional iron content by quantitative susceptibility mapping (QSM) by ≥6% and/or vascular permeability by dynamic contrast enhanced quantitative perfusion (DCEQP) by ≥40% on MRI have been associated with new symptomatic h…
View article: The Generalized 3+3 (G3) Design for Phase I Trials: A Design for Clinicians
The Generalized 3+3 (G3) Design for Phase I Trials: A Design for Clinicians Open
View article: Application and Discussion on the Training of Innovative Graduate Talent Against the Background of “Double First-Class” Construction
Application and Discussion on the Training of Innovative Graduate Talent Against the Background of “Double First-Class” Construction Open
Against the background of the “double first-class” construction, the training of innovative graduate talent has become an important issue in higher education. This article discusses the importance of the training of top graduate innovative…
View article: Changes and Challenges of Graduate Education in the Era of Education Digitalization
Changes and Challenges of Graduate Education in the Era of Education Digitalization Open
With the wave of education digitalization, the reform of graduate education has gradually become an important issue in the reform of innovative personnel training. This paper discusses the necessity of the digital transformation of graduat…
View article: The Generalized 3+3 (G3+3) Design for Phase I Dose-Finding Trials
The Generalized 3+3 (G3+3) Design for Phase I Dose-Finding Trials Open
PURPOSE We propose and demonstrate the feasibility and desirability of a novel model-free dose-finding design for phase I clinical trials. METHODS The Generalized 3+3 (G3+3) design uses a set of simple rules summarized as follows: For 3 or…
View article: A Bayesian Estimator of Sample Size
A Bayesian Estimator of Sample Size Open
We consider a Bayesian estimator of sample size (BESS) and an application to oncology dose optimization clinical trials. BESS is built upon three pillars, Sample size, Evidence from observed data, and Confidence in posterior inference. It …
View article: Bayesian Methods for Information Borrowing in Basket Trials: An Overview
Bayesian Methods for Information Borrowing in Basket Trials: An Overview Open
Basket trials allow simultaneous evaluation of a single therapy across multiple cancer types or subtypes of the same cancer. Since the same treatment is tested across all baskets, it may be desirable to borrow information across them to im…
View article: Global Statistics and Data Sciences (GSDS), BeiGene USA, Fulton, MD
Global Statistics and Data Sciences (GSDS), BeiGene USA, Fulton, MD Open
Pediatric cancer consists of a diverse group of rare diseases. Due to limited patient populations, standard randomized and controlled trials are often infeasible. As a result, single-arm trials are common in pediatric oncology and the use …
View article: The Backfill i3+3 Design for Dose-Finding Trials in Oncology
The Backfill i3+3 Design for Dose-Finding Trials in Oncology Open
We consider a formal statistical design that allows simultaneous enrollment of a main cohort and a backfill cohort of patients in a dose-finding trial. The goal is to accumulate more information at various doses to facilitate dose optimiza…
View article: Editorial. Novel Statistical Methods and Designs for Clinical Trials
Editorial. Novel Statistical Methods and Designs for Clinical Trials Open
View article: Prediction of chronic kidney disease progression using recurrent neural network and electronic health records
Prediction of chronic kidney disease progression using recurrent neural network and electronic health records Open
View article: Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology
Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology Open
We consider a dose-optimization design for first-in-human oncology trial that aims to identify a suitable dose for late-phase drug development. The proposed approach, called the Pharmacometrics-Enabled DOse OPtimization (PEDOOP) design, in…
View article: Data from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Data from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 mon…
View article: Data from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Data from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 mon…
View article: Supplmentary Figures from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Supplmentary Figures from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
Supplmentary Figures
View article: Appendix.pdf from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Appendix.pdf from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
Appendix
View article: Appendix.pdf from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Appendix.pdf from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
Appendix
View article: Supplementary Tables. from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Supplementary Tables. from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
Supplementary tables.
View article: Supplementary Tables. from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Supplementary Tables. from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
Supplementary tables.
View article: Supplmentary Figures from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Supplmentary Figures from Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease Open
Supplmentary Figures
View article: Supplementary Figure 5 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men
Supplementary Figure 5 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men Open
RNASeq quality control data
View article: Supplementary Tables 1-3 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men
Supplementary Tables 1-3 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men Open
Clinico-pathological characteristics of PCa patiens selected for IHC and isolation of CAF. DEG genes between PrF-AA and PrF-EA
View article: Data from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men
Data from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men Open
Progress in prostate cancer racial disparity research has been hampered by a lack of appropriate research tools and better understanding of the tumor biology. Recent gene expression studies suggest that the tumor microenvironment (TME) may…
View article: Supplementary Figure 1 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men
Supplementary Figure 1 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men Open
Assessment of collagen deposition and neoangiogenesis in PCa samples from AA and EA patients. Quantitation of IHC staining of stromal markers
View article: Supplementary Figure 4 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men
Supplementary Figure 4 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men Open
IHC staining and quantitation of FAP in AA andEA patient samples
View article: Supplementary Figure 3 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men
Supplementary Figure 3 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men Open
Differential expression of selected secreted cytokines and densitometric quantitation
View article: Supplementary Figure 5 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men
Supplementary Figure 5 from Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men Open
RNASeq quality control data